Correlation study of PD-L1, CD4, CD8, and PD-1 in primary diffuse large B-cell lymphoma of the central nervous system

被引:1
|
作者
Liu, Bo [1 ]
Yan, Shufang [2 ]
Li, Sijing [4 ]
Zhang, Qian [3 ]
Yang, Meihong [3 ]
Yang, Liuqing [3 ]
Ma, Jiajia [3 ]
Li, Xinxia [3 ]
机构
[1] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Pathol, 3 Qing Chun East Rd, Hangzhou 310020, Zhejiang, Peoples R China
[2] Karamay Cent Hosp, Dept Crit Care Med, 67 Junggar Rd, Karamay 834000, Peoples R China
[3] Xinjiang Med Univ, Tumor Hosp, Dept Pathol, 789 Suzhou Dongjie, Urumqi 830011, Peoples R China
[4] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Hangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
PCNS-DLBCL; PD-L1; Cutoff value; TILs; Prognosis; SERUM LACTATE-DEHYDROGENASE; DEATH LIGAND 1; LUNG-CANCER; T-CELLS; EXPRESSION; SURVIVAL; PREDICTS; METAANALYSIS; INHIBITION; POOR;
D O I
10.1016/j.prp.2022.154008
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We investigated the clinicopathological role of the PD-1/PD-L1 pathway in the primary diffuse large B-cell lymphoma of the central nervous system (PCNS-DLBCL). Standardized staining for PD-L1 was performed by machine staining, and internationally accepted interpretation methods were used. The PD-L1 immunostaining >= 20 % of all cells in slices was defined as high expression of PD-L1. CD4, CD8, and PD-1 tumor-infiltrating lymphocytes (TILs) were enumerated, and the median was defined as the cutoff value. Values higher than the median was defined as high expression. Thirty-four cases (64.2 %) showed high expression of PD-L1. PD-L1 expression was associated with a good prognosis when 20 % was considered as cutoff value and had the smallest P value. By contrast, a low number of CD8+ or PD-1+ TILs was associated with poor prognosis. Patients with low expression of PD-L1 had poor overall survival (P = 0.001), and those with increased CD8 or PD-1 TILs tended to have improved overall survival (P = 0.004 and 0.024, respectively). Low number of monocytes, increased number of lymphocytes, IPI score >= 2, ECOG PS >= 2, LDH >= 250, and Ki67 >= 70 % were independent prognostic factors for OS. In conclusion, PD-L1 expression, CD8 and PD-1 TILs, monocyte status, and ECOG PS might be prognostic markers and therapeutic targets of PCNS-DLBCL.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus
    Marchevsky, Alberto M.
    Watts, Ann E.
    [J]. HUMAN PATHOLOGY, 2017, 60 : 16 - 23
  • [2] Prognostic Value of PD-L1, PD-1 and CD8A in Canine Diffuse Large B-Cell Lymphoma Detected by RNAscope
    Aresu, Luca
    Marconato, Laura
    Martini, Valeria
    Fanelli, Antonella
    Licenziato, Luca
    Foiani, Greta
    Melchiotti, Erica
    Nicoletti, Arturo
    Vascellari, Marta
    [J]. VETERINARY SCIENCES, 2021, 8 (07)
  • [3] PD-L1, PD-1, CD4 and CD8 Expression in Neoplastic and Non-Neoplastic Thymus
    Walts, Ann E.
    Marchevsky, Alberto M.
    [J]. LABORATORY INVESTIGATION, 2016, 96 : 486A - 486A
  • [4] PD-L1, PD-1, CD4 and CD8 Expression in Neoplastic and Non-Neoplastic Thymus
    Walts, Ann E.
    Marchevsky, Alberto M.
    [J]. MODERN PATHOLOGY, 2016, 29 : 486A - 486A
  • [5] Diagnostic Performance of PD-L1 versus PD-1 Expression in Circulating CD20 Cells in Diffuse Large B-Cell Lymphoma
    Saber, Manal Mohamed
    [J]. ANTIBODIES, 2022, 11 (01)
  • [6] CD274 (PD-L1)/PDCD1 (PD-1) expression in de novo and transformed diffuse large B-cell lymphoma
    Kwiecinska, Anna
    Tsesmetzis, Nikolaos
    Ghaderi, Mehran
    Kis, Lorand
    Saft, Leonie
    Rassidakis, George Z.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (05) : 744 - 748
  • [7] Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway
    Haspot, Fabienne
    Fehr, Thomas
    Gibbons, Carrie
    Zhao, Guiling
    Hogan, Timothy
    Honjo, Tasuku
    Freeman, Gordon J.
    Sykes, Megan
    [J]. BLOOD, 2008, 112 (05) : 2149 - 2155
  • [8] High tumoral PD-L1 expression and low PD-1+ or CD8+ tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system
    Kim, Sehui
    Nam, Soo Jeong
    Park, Changhee
    Kwon, Dohee
    Yim, Jeemin
    Song, Seung Geun
    Ock, Chan-Young
    Kim, Young A.
    Park, Sung Hye
    Kim, Tae Min
    Jeon, Yoon Kyung
    [J]. ONCOIMMUNOLOGY, 2019, 8 (09):
  • [9] Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
    Escors, David
    Bocanegra, Ana
    Chocarro, Luisa
    Blanco, Ester
    Pineiro-Hermida, Sergio
    Garnica, Maider
    Fernandez-Rubio, Leticia
    Vera, Ruth
    Arasanz, Hugo
    Kochan, Grazyna
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (21)
  • [10] PD-L1 Expression in Diffuse Large B-Cell Lymphoma (DLBCL) with Clinical Correlation
    Rehman, Aseeb
    Dalvi, Siddhartha
    Presta, Michael
    Nazeer, Tipu
    Ross, Jeffrey S.
    [J]. LABORATORY INVESTIGATION, 2016, 96 : 372A - 372A